This article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...
Read moreThis article explores the significant disparities between the US and Europe regarding orphan drugs a...
Read moreOur market access experts provide an overview of how to get payer scientific advice between Septembe...
Read moreWe explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...
Read moreWe explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...
Read moreWe explore the rapidly evolving market access landscape in respect to digital health applications in...
Read moreDigital health technology played a vital role during the COVID-19 pandemic as there was a rapid usag...
Read moreWe explore the coordinated HTA networks involved in EUnetHTA, define the HTACG and the deliverables ...
Read moreOncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...
Read moreWe explore joint scientific consultations; what they mean and why they are important to manufacturer...
Read more